Loading
Six weeks of chemotherapy before the colon cancer operation, rather than all of it afterwards, shrank tumours, left fewer incomplete resections and cut two-year recurrence from 21.5 to 16.9 percent.
FOxTROT randomly allocated patients with radiologically staged T3-4, N0-2, M0 colon cancer 2:1 to six weeks of oxaliplatin-fluoropyrimidine chemotherapy before surgery plus eighteen afterwards, or to 24 weeks afterwards; patients with RAS wild-type tumours could also be randomised 1:1 to panitumumab or not during the preoperative phase. The primary end point was residual or recurrent disease within two years, with surgical morbidity, histopathological stage, regression grade, completeness of resection and cause-specific mortality as secondary outcomes.
Of 699 patients allocated to neoadjuvant chemotherapy, 674 (96 percent) started and 606 (87 percent) completed it; 30 (4.3 percent) developed obstructive symptoms requiring expedited surgery, but serious postoperative complications were fewer than in the control group.
A UK-led trial that moved part of colon cancer chemotherapy in front of the operation, and showed that tumour regression grade after six weeks predicts recurrence, which is the basis for using the response itself to choose what follows.
Shares Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC), CAPOX (capecitabine, oxaliplatin), Neoadjuvant / adjuvant / perioperative, Oxaliplatin and the tag colorectal-evidence.
Shares Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC), Neoadjuvant / adjuvant / perioperative, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-evidence.
Shares Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Neoadjuvant / adjuvant / perioperative, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation and the tag colorectal-evidence.
Shares CAPOX (capecitabine, oxaliplatin), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Neoadjuvant / adjuvant / perioperative, FOLFOX (5-FU, leucovorin, oxaliplatin) and the tag colorectal-evidence.
Shares Surgery and radiotherapy cure most, get least, CAPOX (capecitabine, oxaliplatin), Oxaliplatin, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation and the tag colorectal-evidence.
Shares Surgery and radiotherapy cure most, get least, Oxaliplatin, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, FOLFOX (5-FU, leucovorin, oxaliplatin) and the tag colorectal-evidence.
Shares Surgery and radiotherapy cure most, get least, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Journal of Clinical Oncology, Colorectal cancer and the tag colorectal-evidence.
Shares Surgery and radiotherapy cure most, get least, Oxaliplatin, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Colorectal cancer and the tag colorectal-evidence.